expensive fail for rochenote their trial size. another reason for roche to seriously consider oncy given oncy's phase 3 ready opportunities which have been de-risked and will be tested with a much smaller patient population. $ saved, $$$$ opportunity.
Roche has reported that its Phase II/III SKYSCRAPER-06 clinical trial of tiragolumab along with Tecentriq (atezolizumab) and chemotherapy as first-line treatment for non-squamous non-small cell lung cancer (NSCLC) failed to meet primary endpoints.
The international, placebo-controlled, randomised, double-blinded trial enrolled 542 priorly untreated patients with locally advanced unresectable or metastatic non-squamous NSCLC.